Last, with the flaw of this one-arm prospective study was the lacking data of those RA controls who receive any cDMARDs other than TAC, We supposed that Gal-9 might play an important role in the immunoregulation of RA and can provide efficacy and prognostic information in RA patients, reflecting patient response to TAC-based treatment. The gene discussed is LGALS9; the disease is rheumatoid arthritis.